Duchenne News Tags: Edgewise Therapeutics

February 13, 2024
Edgewise shares a press release announcing FDA granting Fast Track designation for EDG-5506 for the treatment of Duchenne.
December 19, 2023
Edgewise announces launch of educational website dedicated to the Becker muscular dystrophy community.
December 19, 2023
Edgewise releases Winter 2023 newsletter.
November 30, 2023
Edgewise announces FDA granted EDG-5506 Orphan Drug Designation for Duchenne and Becker and Rare Pediatric Disease Designation for Duchenne.
October 26, 2023
Edgewise Therapeutics announces an expansion of their clinical development program of EDG-5506.
June 27, 2023
Edgewise Therapeutics announces positive 12-month topline results from the ongoing ARCH study for Becker muscular dystrophy
April 7, 2023
On March 30, 2023, Edgewise Therapeutics announced the publication of the article, “Modulating fastskeletal muscle contraction protects skeletal muscle in the animal models of Duchenne muscular dystrophy,” in the Journal...
September 12, 2022
On Sept. 12, 2022, Edgewise Therapeutics released positive 4-month interim data from their open label study in individuals with Becker muscular dystrophy.
September 7, 2022
On Sept. 7, 2022, Edgewise announced that the FDA has authorized its Phase 2 clinical trial for the treatment of Duchenne. They expect to begin dosing participants in the fourth...
July 14, 2022
On July 12, 2022, Edgewise Therapeutics shared a press release announcing the opening of the CANYON Phase 2 clinical trial of their investigational compound, EDG-5506, in individuals with Becker muscular...
Edgewise Duchenne News
June 21, 2022
On June 20, 2022, Edgewise Therapeutics announced positive results from the ARCH open label study of EDG-5506.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open